4.5 Article

LENGTH-DEPENDENT AXO-TERMINAL DEGENERATION AT THE NEUROMUSCULAR SYNAPSES OF TYPE II MUSCLE IN SOD1 MICE

Journal

NEUROSCIENCE
Volume 312, Issue -, Pages 179-189

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2015.11.018

Keywords

motor neuron disease; neuromuscular; degeneration; innervation; motor axon; sprouting

Categories

Funding

  1. Muscular Dystrophy Association
  2. National Institute of Neurological Disease and Stroke of the NIH [R01NS079339]

Ask authors/readers for more resources

In motor neuron diseases, there is a prolonged period of time before any clinical symptoms begin to appear. During this time, distal axonal degeneration, or dying back axonopathy, begins to occur before the onset of clinical symptoms and motor neuron death. This preclinical degeneration is a hallmark of motor neuron diseases in both animal models and human patients. Generally, in muscles with mixed fiber types, distal degeneration occurs in fast-fatigable alpha-motor axons innervating type IIb muscle fibers before axons innervating slow, type I muscle fibers. We investigated whether the dying back axonopathy in a pure fast-fatigable alpha-motor axon nerve is a length-dependent process. The lateral thoracic nerve (LTN) exclusively consists of motor nerves that innervate the very thin cutaneous maximus muscle (CMM) that solely contains type II neuromuscular synapses. We characterized the LTN and CMM synapses both morphologically and physiologically in the superoxide dismutase 1 (SOD1) mutant mouse model of amyotrophic lateral sclerosis (ALS). By 60 days of age, there was a significant dying back phenomenon at the caudal region while the rostral region remained intact. The longer axons innervating the caudal region appear to be more susceptible to degeneration in the SOD1 mouse indicating that the axonal degeneration of motor neurons innervating type II fibers is a length-dependent process. Additionally, we identified how the simplicity of the LTN-CMM system offers a better method to investigate axon degeneration in an ALS mouse model and may be used to investigate possible therapeutic compounds for axon protection and regeneration. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available